预约演示
更新于：2026-04-20
Hydroxysafflor Yellow A
羟基红花黄色素A
更新于：2026-04-20
概要
基本信息
原研机构 |
在研机构 |
权益机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H32O16 |
InChIKeyLIPJRCGLQNIXGO-ONZBGLOFSA-N |
CAS号78281-02-4 |
关联
10
项与 羟基红花黄色素A 相关的临床试验ITMCTR2025001862
Hydroxysafflor Yellow A Injection for Large-Artery Atherosclerotic Acute Ischemic Stroke: Efficacy and Safety in a Randomized Clinical Trial
CTR20231772
健康受试者单次、多次静脉滴注注射用羟基红花黄色素A的药代动力学和安全性的开放、单中心研究
ChiCTR2300072306
Pharmacokinetic profile and safety of hydroxysafflor yellow A following single and multiple intravenous administration in healthy Chinese volunteers: an open-labeled, single-center study
100 项与 羟基红花黄色素A 相关的临床结果
登录后查看更多信息
100 项与 羟基红花黄色素A 相关的转化医学
登录后查看更多信息
100 项与 羟基红花黄色素A 相关的专利（医药）
登录后查看更多信息
655
项与 羟基红花黄色素A 相关的文献（医药）2026-04-01PHYTOMEDICINE
The combination of paeoniflorin and hydroxysafflor yellow A alleviated pulmonary thrombosis by inhibiting platelet-neutrophil interaction via the P-selectin-PSGL-1 signaling axis
Article
作者: Pan, Tao ; Zhang, Zhi-Sen ; Chang, Jing ; Zhang, Yue ; Feng, Yuxin ; Shang, Ting ; Shen, Ru
Sepsis is a life-threatening syndrome characterized by an inflammatory cytokine storm and disseminated intravascular coagulation (DIC). The interplay between platelets and neutrophils is a key driver of the thrombosis-inflammation vicious cycle in sepsis, contributing to a detrimental feedback loop that exacerbates DIC and amplifies inflammatory cytokine storm. However, limited approaches are available for specifically targeting platelet-neutrophil crosstalk in sepsis. Xuebijing injection (XBJ), clinically used as an add-on for sepsis treatment, has been shown to reduce inflammatory cytokines release and alleviate microcirculation disturbances. In this study, we formulated a novel pharmaceutical composition (C0127-2) by combining paeoniflorin and hydroxysafflor yellow A according to their contents in XBJ (the two components with the highest content), demonstrating that C0127-2 effectively prevented sepsis-induced acute lung injury (ALI) and pulmonary thrombosis. We further verified this protection was achieved by disrupting the aggregates between platelets and neutrophils. Mechanistically, C0127-2 exerted its anti-crosstalk effects between platelet and neutrophil by inhibiting the P-selectin-PSGL-1 signaling axis, a core signaling axis to mediate platelet-neutrophil interaction. Collectively, we identified the key active constituents of XBJ, paving the way for developing a novel multi-component drug with specific ingredients for sepsis treatment. And we underscored a promising therapeutic strategy for sepsis that combining anti-inflammation and anti-coagulation effects, offering a potential management for improving patient outcomes.
2026-03-01FITOTERAPIA
Yiqi Huoxue formula attenuates pressure overload-induced chronic heart failure with insomnia via regulation of RORα-mediated mitochondrial fuction
Article
作者: Li, Fang ; Huang, Zhekai ; Lin, Yangyang ; Chen, Yangxian ; Rong, Libao ; Kou, Junping ; Gao, Lan
Yiqi Huoxue (YQHX) formula is an empirical prescription for the treatment of qi deficiency and blood stasis syndrome in traditional Chinese medicine (TCM). Qi deficiency and blood stasis is one of the typical TCM syndromes in heart failure. However, little is known about the mechanism of the YQHX formula in treating heart failure patients with qi deficiency and blood stasis syndrome. This study aimed to systematically investigate the therapeutic mechanisms of YQHX formula in heart failure with comorbid insomnia. HPLC-Q-TOF-MS/MS analysis identified twenty-one bioactive components in the YQHX formula, including caffeic acid, hydroxysafflor yellow A, and salvianolic acid B. Research results in vivo revealed that treatment with YQHX formula significantly improved cardiac function and alleviated myocardial injury in the mice model of TAC-induced HF. Meanwhile, YQHX formula effectively suppressed pressure overload-induced cardiac hypertrophy and significantly ameliorated insomnia and anxiety-like behaviors through modulation of neurotransmitter systems. Mechanistically, YQHX formula upregulated RORα expression, thereby facilitating mitophagy and restoring mitochondrial dynamics homeostasis. Consistent with these in vivo findings, in vitro experiments demonstrated that YQHX formula markedly inhibited Ang II-induced cardiomyocyte hypertrophy, enhanced mitochondrial membrane potential (ΔΨm), reduced reactive oxygen species (ROS) production and preserved mitochondrial structural integrity. Our findings identify the promotion of the RORα pathway as the underlying mechanism through which the YQHX formula alleviates heart failure and comorbid insomnia, offering new insights into the prevention and treatment of cardiovascular diseases accompanied by sleep disturbances.
2026-02-01BRAIN RESEARCH BULLETIN
Hydroxysafflor yellow A protects against ischemic stroke-associated Weber syndrome by inhibiting oxidative stress and alleviating DNA damage
Article
作者: Zhang, Man ; Geng, Wujun ; Wan, Haitong ; Yang, Jiehong ; Zhou, Huifen ; Zeng, Miaolin ; Zeng, Lian
Weber syndrome, characterized by ipsilateral oculomotor palsy and contralateral hemiplegia, frequently occurs in ischemic stroke cases and is difficult to recover from. Hydroxysafflor yellow A (HSYA), a bioactive component present in Carthamus tinctorius L. and the standardized preparation Danhong injection, has shown protective effects in animal models of various neurological diseases. This research was conducted to evaluate the therapeutic potential of HSYA in ischemic stroke-associated Weber syndrome, while elucidating its mechanistic basis. A rat MCAO model was induced to detect the effects of HSYA on motor dysfunction, ipsilateral ptosis and neuronal death in the right cerebral peduncle. By western blot, immunohistochemistry staining and immunofluorescence staining, we explored the involvement of oxidative stress and DNA damage in HSYA's neuroprotective action. HSYA treatment for consecutive 7 days significantly improved neurological function, grip strength, and asymmetry of bilateral eye clefts in CI/R-injured rats. HSYA also reduced cerebral infarction, preserved neuronal survival, and mitigated histopathological damage in the cerebral peduncle. Mechanistically, HSYA alleviated oxidative stress by preserving CAT, GSH, and SODM levels while inhibiting iNOS overexpression. Furthermore, CI/R injury triggered substantial DNA damage in the cerebral peduncle, as indicated by upregulated levels of 53BP1 and γ-H2A.X. Contents of PARP1, AIF, and MIF were also significantly elevated, accompanied by obvious upregulation of apoptotic cell death, while HSYA treatment effectively attenuated these deleterious effects. HSYA protects against CI/R injury and associated Weber syndrome, and the mechanism involves suppressing oxidative stress and limiting DNA injury.
100 项与 羟基红花黄色素A 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脑卒中 | 申请上市 | 中国 | 2015-01-19 | |
| 急性缺血性卒中 | 临床3期 | 中国 | 2021-02-18 | |
| 脑梗塞 | 临床3期 | 中国 | 2015-11-05 | |
| 血栓性脑梗塞 | 临床3期 | 中国 | 2015-11-05 | |
| 脑出血 | 临床前 | 中国 | 2025-11-01 | |
| 缺血性卒中 | 临床前 | 中国 | 2025-09-01 | |
| 脑缺血 | 临床前 | 中国 | 2025-03-26 | |
| 脑缺血 | 临床前 | 中国 | 2025-03-26 | |
| 神经炎症 | 临床前 | 中国 | 2025-03-26 | |
| 神经炎症 | 临床前 | 中国 | 2025-03-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用